@NatRevDrugDisc @CellMedica @MDAndersonNews @NEJM $GILD Gilead, Kite and oNKo-innate announced a research collaboration to discover cancer immunotherapies focused on natural killer (NK) cells.

Gilead will pay an undisclosed upfront and milestones. $KITE @oNKo_innate

Relevant to $FATE $JNJ $TAK $NK

https://t.co/E5GIdl6m3I